<DOC>
	<DOCNO>NCT02843412</DOCNO>
	<brief_summary>Background : Gastric cancer ( GC ) major global health concern second lead cause cancer death worldwide . Amplification Her2/neu gene and/or overexpression Her2/neu protein observe GC . Trastuzumab ( Herceptinâ„¢ ) anti-Her2/neu antibody , successfully apply GC . However , intratumoral heterogeneity Her2/neu overexpression amplification GC notice . The investigator investigate significance evaluate Her2/neu expression different paraffin block tumor tissue GC . Methods : 2000 GC patient ten center , patient divide cohort use one tumor tissue paraffin block ( cohort 1 , n=1000 ) cohort use dual tumor tissue paraffin block ( cohort 2 , n=1000 ) evaluate Her2/neu expression status immunohistochemistry ( IHC ) . In cohort 2 , investigator combine result two different paraffin block use high one final score .</brief_summary>
	<brief_title>The Clinical Study Assessing HER-2 Expression Gastric Cancer With Extra Tumor Tissue Paraffin Blocks Using Immunohistochemistry</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<criteria>Undergone curative surgery gastric cancer , 1880 year old .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Gastric cancer</keyword>
	<keyword>Her2/neu</keyword>
	<keyword>Dual paraffin block</keyword>
	<keyword>Trastuzumab</keyword>
	<keyword>Clinical Prospective Multicenter Cohort Study</keyword>
</DOC>